Can a lower dose of rivaroxaban be safer for kidney patients on dialysis?

NCT ID NCT05410275

Recruiting now Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing three different low doses of the blood thinner rivaroxaban in 10 adults on chronic hemodialysis. The goal is to see how the drug behaves in the body and how much it thins the blood, to find a dose that might lower bleeding risks. Participants will take each dose for three days, and researchers will measure drug levels and clotting activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rivaroxaban
What this could lead to: If successful, this could help determine a safer dose of rivaroxaban for dialysis patients who need blood thinners, potentially reducing bleeding risks.
What could go wrong: This is a very small early-phase study with only 10 participants, so results may not apply to all patients. The drug may still cause bleeding or not work as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEMODIALYSIS PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEMODIALYSIS PATIENTS

Contacts and locations

Locations

01-Arauco
RECRUITING

Tours, France
02-TOURS
RECRUITING

Tours, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.